Non-Current Assets

Equity Method Investments

Linde Equity Method Investments decreased by 5.4% to $2.02B in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 5.4%, from $2.13B to $2.02B. Over 5 years (FY 2020 to FY 2025), Equity Method Investments shows relatively stable performance with a -0.5% CAGR.

Analysis

StatementBalance Sheet Statement
SectionNon-Current Assets
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ4 2017
Last reportedQ4 2025Feb 25, 2026

How to read this metric

An increase indicates strategic expansion through partnerships or joint ventures, while a decrease may signal divestments or impairment.

Detailed definition

These are investments in entities where the company exercises significant influence but does not have full control. The...

Peer comparison

Varies significantly based on corporate strategy; common in healthcare companies that partner with biotech startups or specialized diagnostic firms.

Metric ID: equity_method_investments

Historical Data

5 periods
 Q4 '21Q4 '22Q4 '23Q4 '24Q4 '25
Value$2.62B$2.35B$2.19B$2.13B$2.02B
QoQ Change-10.3%-6.8%-2.7%-5.4%
YoY Change-10.3%-6.8%-2.7%-5.4%
Range$2.02B$2.62B
CAGR-23.1%
Avg YoY Growth-6.3%
Median YoY Growth-6.1%
Current Streak4+ quarters decline

Frequently Asked Questions

What is Linde's equity method investments?
Linde (LIN) reported equity method investments of $2.02B in Q4 2025.
How has Linde's equity method investments changed year-over-year?
Linde's equity method investments decreased by 5.4% year-over-year, from $2.13B to $2.02B.
What is the long-term trend for Linde's equity method investments?
Over 5 years (2020 to 2025), Linde's equity method investments has grown at a -0.5% compound annual growth rate (CAGR), from $2.06B to $2.02B.
What does equity method investments mean?
The value of investments in other companies where the firm has significant influence but not total control.